Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elotuzumab with ASCT in Elderly Multiple Myeloma
NCT03393273Phase 2Withdrawn
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2018
- Primary completion
- Jan 2019
- Countries
- 1
01
Overview
A Phase 2 trial of elotuzumab in multiple myeloma (MM), sponsored by Assistance publique - Hôpitaux de Paris. Planned start Feb 2018; status: withdrawn.
02
Drugs
elotuzumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03393273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03393273.